Genetic Analysis of Leukocyte Type-I Interferon Production and Risk of Coronary Artery Disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 6, 2015, Pages 1456-1462

  Nelson, Christopher P ^a,b   Schunkert, Heribert ^c,d   Samani, Nilesh J ^a,b   Erridge, Clett ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

coronary artery disease; genetic association; immune system; systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BIOLOGICAL MARKER; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

AICARDI GOUTIERES SYNDROME; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOREGULATION; INTERFERON PRODUCTION; LEUKOCYTE; MENDELIAN RANDOMIZATION ANALYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPONDYLOENCHONDRODYSPLASIA; SYSTEMIC LUPUS ERYTHEMATOSUS; BIOSYNTHESIS; GENETICS; METABOLISM; RISK FACTOR;

CORONARY ARTERY DISEASE; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERON-ALPHA; LEUKOCYTES; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84933056724     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304925     Document Type: Article

References (35)

1. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:969-979. doi: 10.1161/ATVBAHA.110.207415.
2. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373-384. doi: 10.1038/ni.1863.
3. Levy Z, Rachmani R, Trestman S, Dvir A, Shaish A, Ravid M, Harats D. Low-dose interferon-alpha accelerates atherosclerosis in an LDL receptor-deficient mouse model. Eur J Intern Med. 2003;14:479-483. doi: 10.1016/j.ejim.2003.08.010.
4. Goossens P, Gijbels MJ, Zernecke A, Eijgelaar W, Vergouwe MN, van der Made I, Vanderlocht J, Beckers L, Buurman WA, Daemen MJ, Kalinke U, Weber C, Lutgens E, de Winther MP. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab. 2010;12:142-153. doi: 10.1016/j.cmet.2010.06.008.
5. Li J, Fu Q, Cui H, Qu B, Pan W, Shen N, Bao C. Interferon-? priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-? and atherosclerosis in lupus. Arthritis Rheum. 2011;63:492-502. doi: 10.1002/art.30165.
6. Zhang LN, Velichko S, Vincelette J, Fitch RM, Vergona R, Sullivan ME, Croze E, Wang YX. Interferon-beta attenuates angiotensin II-accelerated atherosclerosis and vascular remodeling in apolipoprotein E deficient mice. Atherosclerosis. 2008;197:204-211. doi: 10.1016/j.atherosclerosis.2007.03.019.
7. Daissormont IT, Christ A, Temmerman L, et al. Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity. Circ Res. 2011;109:1387-1395. doi: 10.1161/CIRCRESAHA.111.256529.
8. Koulis C, Chen YC, Hausding C, Ahrens I, Kyaw TS, Tay C, Allen T, Jandeleit-Dahm K, Sweet MJ, Akira S, Bobik A, Peter K, Agrotis A. Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2014;34:516-525. doi: 10.1161/ATVBAHA.113.302407.
9. Kahlenberg JM, Kaplan MJ. Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu Rev Med. 2013;64:249-263. doi: 10.1146/annurev-med-060911-090007.
10. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFNalpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8:492-502. doi: 10.1038/sj.gene.6364408.
11. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000;43:1431-1442.
12. Bronson PG, Chaivorapol C, Ortmann W, Behrens TW, Graham RR. The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol. 2012;24:530-537. doi: 10.1016/j.coi.2012.07.008.
13. de Craen AJ, Posthuma D, Remarque EJ, van den Biggelaar AH, Westendorp RG, Boomsma DI. Heritability estimates of innate immunity: an extended twin study. Genes Immun. 2005;6:167-170. doi: 10.1038/sj.gene.6364162.
14. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Côte R, Grover SA, Fortin PR, Clarke AE, Senécal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-2337.
15. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, Muggeo M, Xu Q, Wick G, Poewe W, Willeit J. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation. 2001;103:1064-1070.
16. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1-22.
17. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN); Harley JB, Alarcón-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40:204-210. doi: 10.1038/ng.81.
18. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. Genome-wide pathway analysis of genome-wide association studies on systemic lupus erythematosus and rheumatoid arthritis. Mol Biol Rep. 2012;39:10627-10635. doi: 10.1007/s11033-012-1952-x.
19. Kozyrev SV, Abelson AK, Wojcik J, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet. 2008;40:211-216. doi: 10.1038/ng.79.
20. Graham RR, Cotsapas C, Davies L, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet. 2008;40:1059-1061. doi: 10.1038/ng.200.
21. Lessard CJ, Adrianto I, Kelly JA, et al; Marta E. Alarcón-Riquelme on behalf of the BIOLUPUS and GENLES Networks. Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet. 2011;88:83-91. doi: 10.1016/j.ajhg.2010.11.014.
22. Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med. 2008;358:900-909. doi: 10.1056/NEJMoa0707865.
23. Lichtman EI, Helfgott SM, Kriegel MA. Emerging therapies for systemic lupus erythematosus-focus on targeting interferon-alpha. Clin Immunol. 2012;143:210-221. doi: 10.1016/j.clim.2012.03.005.
24. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 2004;101:10679-10684. doi: 10.1073/pnas.0403249101.
25. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor. J Clin Invest. 2005;115:3149-3156. doi: 10.1172/JCI25482.
26. Cole JE, Navin TJ, Cross AJ, Goddard ME, Alexopoulou L, Mitra AT, Davies AH, Flavell RA, Feldmann M, Monaco C. Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci U S A. 2011;108:2372-2377. doi: 10.1073/pnas.1018515108.
27. Salagianni M, Galani IE, Lundberg AM, et al. Toll-like receptor 7 protects from atherosclerosis by constraining inflammatory macrophage activation. Circulation. 2012;126:952-962. doi: 10.1161/CIRCULATIONAHA.111.067678.
28. Leonard D, Svenungsson E, Sandling JK, et al. Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants. Circ Cardiovasc Genet. 2013;6:255-263. doi: 10.1161/CIRCGENETICS.113.000044.
29. Versteeg D, Hoefer IE, Schoneveld AH, de Kleijn DP, Busser E, Strijder C, Emons M, Stella PR, Doevendans PA, Pasterkamp G. Monocyte tolllike receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve. Heart. 2008;94:770-776. doi: 10.1136/hrt.2007.117259.
30. Van Den Biggelaar AH, De Craen AJ, Gussekloo J, Huizinga TW, Heijmans BT, Frölich M, Kirkwood TB, Westendorp RG. Inflammation underlying cardiovascular mortality is a late consequence of evolutionary programming. FASEB J. 2004;18:1022-1024. doi: 10.1096/fj.03-1162fje.
31. Elsenberg EH, Hillaert MA, den Ruijter HM, Sels JW, Scholtes VP, Nathoe HM, Kuiper J, Jukema JW, Doevendans PA, Pasterkamp G, Hoefer IE. Toll-Like Receptor induced CD11b and L-selectin response in patients with coronary artery disease. PLoS One. 2013;8:e60467. doi: 10.1371/journal.pone.0060467.
32. Larsen MH, Albrechtsen A, Thørner LW, Werge T, Hansen T, Gether U, Haastrup E, Ullum H. Genome-wide association study of genetic variants in LPS-stimulated IL-6, IL-8, IL-10, IL-1ra and TNF-? cytokine response in a Danish cohort. PLoS One. 2013;8:e66262. doi: 10.1371/journal. pone.0066262.
33. Lee MN, Ye C, Villani AC, et al. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science. 2014;343:1246980. doi: 10.1126/science.1246980.
34. Fairfax BP, Humburg P, Makino S, Naranbhai V, Wong D, Lau E, Jostins L, Plant K, Andrews R, McGee C, Knight JC. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science. 2014;343:1246949. doi: 10.1126/science.1246949.
35. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, Davey Smith G, Sterne JA. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res. 2012;21:223-242. doi: 10.1177/0962280210394459.